ArticleFrontiers in immunology2020

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.

Xuan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.